The Chinese Pharmaceutical Market to 2030
The Chinese government has sought a complete overhaul of its healthcare sector via the ‘Healthy China 2020’ and subsequent ‘Healthy China 2030’ program. Within the program, new Healthcare reforms, augmented by the 13th Five Year Plan has paved the way both foreign as well as local pharmaceutical companies.
In addition to, or in tandem with, governmental direction, China has seen an increase of people moving from rural to city locales, witnessed an increase in the middle class, witnessed average salaries rise and seen life expectancy increase also. These factors have driven the China Pharmaceutical market, and will broadly continue across the forecast period 2020-2030.
This report studies the China pharmaceutical market in terms of Market Structure, encompassing the study and impact analysis of reforms; it also studies the regulatory structure and distributor channel structures. The China pharmaceutical market section gives a detailed market overview, qualitative analysis of the factors responsible for driving and restraining growth, nature of the market, competitive landscape, PE/VCs funding as well as M&As, the section also details future outlook.
Within this report the China pharmaceutical market has been segmented based on the distribution channel markets, by drug types and also by key therapeutics markets. The market size estimates and forecasts for the period 2020 to 2030 have been provided for each of the segments, in terms of $ bn, considering 2019 as the base year for calculations. The CAGR (%) of each market segment for the forecast period 2020 to 2030 has also been provided along with market size estimations.
The report concludes with the competitive landscape and Company Profiles of key market players in this market, as of 2019. The market players profiled in this report include Sino Biopharm, CSPC, Fosun Pharma, Shanghai Pharmaceuticals, AstraZeneca China, and Pfizer China.
In addition to, or in tandem with, governmental direction, China has seen an increase of people moving from rural to city locales, witnessed an increase in the middle class, witnessed average salaries rise and seen life expectancy increase also. These factors have driven the China Pharmaceutical market, and will broadly continue across the forecast period 2020-2030.
This report studies the China pharmaceutical market in terms of Market Structure, encompassing the study and impact analysis of reforms; it also studies the regulatory structure and distributor channel structures. The China pharmaceutical market section gives a detailed market overview, qualitative analysis of the factors responsible for driving and restraining growth, nature of the market, competitive landscape, PE/VCs funding as well as M&As, the section also details future outlook.
Within this report the China pharmaceutical market has been segmented based on the distribution channel markets, by drug types and also by key therapeutics markets. The market size estimates and forecasts for the period 2020 to 2030 have been provided for each of the segments, in terms of $ bn, considering 2019 as the base year for calculations. The CAGR (%) of each market segment for the forecast period 2020 to 2030 has also been provided along with market size estimations.
The report concludes with the competitive landscape and Company Profiles of key market players in this market, as of 2019. The market players profiled in this report include Sino Biopharm, CSPC, Fosun Pharma, Shanghai Pharmaceuticals, AstraZeneca China, and Pfizer China.
CHAPTER 1 EXECUTIVE SUMMARY
1.1 REPORT DESCRIPTION
1.2 MARKET SEGMENTATION
1.3 RESEARCH METHODOLOGY
CHAPTER II DRIVERS & RESTRAINTS OF THE CHINESE PHARMACEUTICAL MARKET
CHAPTER III CHINA HEALTHCARE INDICATORS VS GLOBAL HEALTHCARE INDICATORS
3.1 DEMOGRAPHIC INDICATORS
3.2 HEALTHCARE EXPENDITURE
3.3 PRIVATE EQUITY/VENTURE CAPITAL INVESTMENTS
3.4 IMPLICATIONS FROM US - CHINA TRADE WAR ON CHINA PHARMACEUTICAL MARKET
3.4.1. No Impact on Chinese APIs
3.4.2. Adverse Impact on Chinese Outbound Investments, M&As
CHAPTER IV CHINA PHARMACEUTICAL MARKET STRUCTURE
4.1 HEALTHY CHINA 2020 REFORMS - REVIEW
4.2 HEALTHY CHINA 2030 REFORMS – IMPACT ON PHARMACEUTICAL MARKET
4.3 REGULATORY STRUCTURE
4.3.1. Regulatory Authorities
4.3.2. Current Regulatory Policies for Drugs/Pharmaceuticals
4.3.3. Registration Process/Approval for Domestic and Imported Drugs
4.3.4. Intellectual Property Rights/Patent law
4.3.5. Pricing and Reimbursement
4.4 DISTRIBUTION STRUCTURE
4.4.1. Average Sales Force Size
4.4.2. Bribery Penalties - Indications of Changing Pharmaceutical Distribution Practices
4.4.3. China Hospitals Sales, 2020 - 2030 ($ bn)
4.4.4. China Retail Pharmacies Sales, 2020 - 2030 ($ bn)
4.4.5. China e-Pharmacies Sales, 2020 - 2030 ($ bn)
CHAPTER V CHINA PHARMACEUTICAL MARKET
5.1 OVERVIEW
5.2 GROWTH DRIVERS
5.2.1. Higher Proportion of Geriatric Population and Increased Incidence of ‘Lifestyle’ Diseases
5.2.2. Rising Affordability
5.2.3. Supply-Side Reforms Augment Demand
5.3 BARRIERS/RESTRAINTS
5.3.1. Non-Uniform Reimbursements
5.3.2. Low R&D% Investment
5.4 COMPETITIVE LANDSCAPE
5.4.1. Foreign Companies - Key Operating/High ROI Therapeutic Areas
5.4.2. Domestic Companies - Key Operating/High ROI Therapeutic Areas
5.5 TRENDS AND FUTURE OUTLOOK
5.5.1. Massive in-bound funds flow to spur local R&D/innovation
5.5.2. Reverse brain-drain in China pharmaceutical market
5.5.3. Digital customer engagement becoming the necessary evil
CHAPTER VI CHINA PHARMACEUTICAL MARKET, BY TYPE, 2020 - 2030 ($ BN)
6.1 CHINA SMALL MOLECULE DRUGS MARKET, 2020 – 2030 ($ BN)
6.1.1. China Patented Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.1.2. China Generic Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.2 CHINA BIOLOGICS MARKET, 2020 – 2030 ($ BN)
6.2.1. China Patented Biologics Market, 2020 – 2030 ($ bn)
6.2.2. China Biosimilars Market, 2020 – 2030 ($ bn)
6.2.3. China Vaccines Market, 2020 – 2030 ($ bn)
CHAPTER VII CHINA APIS MARKET, 2020 - 2030 ($ BN)
CHAPTER VIII CHINA PHARMACEUTICAL MARKET, BY KEY THERAPEUTICS, 2020 - 2030 ($ BN)
8.1 CHINA CARDIOVASCULAR DRUGS MARKET, 2020 – 2030 ($ BN)
8.2 CHINA ANTI-INFECTIVE DRUGS MARKET, 2020 – 2030 ($ BN)
8.3 CHINA ONCOLOGY DRUGS MARKET, 2020 – 2030 ($ BN)
8.4 CHINA DIABETES DRUGS MARKET, 2020 – 2030 ($ BN)
CHAPTER IX COMPANY PROFILES
9.1. SINO BIOPHARMACEUTICAL LTD.
9.1.1. Background
9.1.2. Business Structure - China
9.1.3. Products/Services - China
9.1.4. Distribution Network - China
9.1.5. Growth strategy - China
9.1.6. Financial Information - China
9.2. CSPC PHARMACEUTICAL GROUP LTD.
9.2.1. Background
9.2.2. Business Structure - China
9.2.3. Products/Services - China
9.2.4. Distribution Network - China
9.2.5. Growth strategy - China
9.2.6. Financial Information - China
9.3. ASTRAZENECA CHINA
9.3.1. Background
9.3.2. Business Structure - China
9.3.3. Products/Services - China
9.3.4. Distribution Network - China
9.3.5. Growth strategy - China
9.3.6. Financial Information - China
9.4. PFIZER CHINA
9.4.1. Background
9.4.2. Business Structure - China
9.4.3. Products/Services - China
9.4.4. Distribution Network - China
9.4.5. Growth strategy - China
9.4.6. Financial Information - China
9.5. SHANGHAI PHARMACEUTICALS HOLDING COMPANY LTD.
9.5.1. Background
9.5.2. Business Structure - China
9.5.3. Products/Services - China
9.5.4. Distribution Network - China
9.5.5. Growth strategy - China
9.5.6. Financial Information - China
9.6. FOSUN PHARMA
9.6.1. Background
9.6.2. Business Structure - China
9.6.3. Products/Services - China
9.6.4. Distribution Network - China
9.6.5. Growth strategy - China
9.6.6. Financial Information - China
1.1 REPORT DESCRIPTION
1.2 MARKET SEGMENTATION
1.3 RESEARCH METHODOLOGY
CHAPTER II DRIVERS & RESTRAINTS OF THE CHINESE PHARMACEUTICAL MARKET
CHAPTER III CHINA HEALTHCARE INDICATORS VS GLOBAL HEALTHCARE INDICATORS
3.1 DEMOGRAPHIC INDICATORS
3.2 HEALTHCARE EXPENDITURE
3.3 PRIVATE EQUITY/VENTURE CAPITAL INVESTMENTS
3.4 IMPLICATIONS FROM US - CHINA TRADE WAR ON CHINA PHARMACEUTICAL MARKET
3.4.1. No Impact on Chinese APIs
3.4.2. Adverse Impact on Chinese Outbound Investments, M&As
CHAPTER IV CHINA PHARMACEUTICAL MARKET STRUCTURE
4.1 HEALTHY CHINA 2020 REFORMS - REVIEW
4.2 HEALTHY CHINA 2030 REFORMS – IMPACT ON PHARMACEUTICAL MARKET
4.3 REGULATORY STRUCTURE
4.3.1. Regulatory Authorities
4.3.2. Current Regulatory Policies for Drugs/Pharmaceuticals
4.3.3. Registration Process/Approval for Domestic and Imported Drugs
4.3.4. Intellectual Property Rights/Patent law
4.3.5. Pricing and Reimbursement
4.4 DISTRIBUTION STRUCTURE
4.4.1. Average Sales Force Size
4.4.2. Bribery Penalties - Indications of Changing Pharmaceutical Distribution Practices
4.4.3. China Hospitals Sales, 2020 - 2030 ($ bn)
4.4.4. China Retail Pharmacies Sales, 2020 - 2030 ($ bn)
4.4.5. China e-Pharmacies Sales, 2020 - 2030 ($ bn)
CHAPTER V CHINA PHARMACEUTICAL MARKET
5.1 OVERVIEW
5.2 GROWTH DRIVERS
5.2.1. Higher Proportion of Geriatric Population and Increased Incidence of ‘Lifestyle’ Diseases
5.2.2. Rising Affordability
5.2.3. Supply-Side Reforms Augment Demand
5.3 BARRIERS/RESTRAINTS
5.3.1. Non-Uniform Reimbursements
5.3.2. Low R&D% Investment
5.4 COMPETITIVE LANDSCAPE
5.4.1. Foreign Companies - Key Operating/High ROI Therapeutic Areas
5.4.2. Domestic Companies - Key Operating/High ROI Therapeutic Areas
5.5 TRENDS AND FUTURE OUTLOOK
5.5.1. Massive in-bound funds flow to spur local R&D/innovation
5.5.2. Reverse brain-drain in China pharmaceutical market
5.5.3. Digital customer engagement becoming the necessary evil
CHAPTER VI CHINA PHARMACEUTICAL MARKET, BY TYPE, 2020 - 2030 ($ BN)
6.1 CHINA SMALL MOLECULE DRUGS MARKET, 2020 – 2030 ($ BN)
6.1.1. China Patented Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.1.2. China Generic Small Molecule Drugs Market, 2020 – 2030 ($ bn)
6.2 CHINA BIOLOGICS MARKET, 2020 – 2030 ($ BN)
6.2.1. China Patented Biologics Market, 2020 – 2030 ($ bn)
6.2.2. China Biosimilars Market, 2020 – 2030 ($ bn)
6.2.3. China Vaccines Market, 2020 – 2030 ($ bn)
CHAPTER VII CHINA APIS MARKET, 2020 - 2030 ($ BN)
CHAPTER VIII CHINA PHARMACEUTICAL MARKET, BY KEY THERAPEUTICS, 2020 - 2030 ($ BN)
8.1 CHINA CARDIOVASCULAR DRUGS MARKET, 2020 – 2030 ($ BN)
8.2 CHINA ANTI-INFECTIVE DRUGS MARKET, 2020 – 2030 ($ BN)
8.3 CHINA ONCOLOGY DRUGS MARKET, 2020 – 2030 ($ BN)
8.4 CHINA DIABETES DRUGS MARKET, 2020 – 2030 ($ BN)
CHAPTER IX COMPANY PROFILES
9.1. SINO BIOPHARMACEUTICAL LTD.
9.1.1. Background
9.1.2. Business Structure - China
9.1.3. Products/Services - China
9.1.4. Distribution Network - China
9.1.5. Growth strategy - China
9.1.6. Financial Information - China
9.2. CSPC PHARMACEUTICAL GROUP LTD.
9.2.1. Background
9.2.2. Business Structure - China
9.2.3. Products/Services - China
9.2.4. Distribution Network - China
9.2.5. Growth strategy - China
9.2.6. Financial Information - China
9.3. ASTRAZENECA CHINA
9.3.1. Background
9.3.2. Business Structure - China
9.3.3. Products/Services - China
9.3.4. Distribution Network - China
9.3.5. Growth strategy - China
9.3.6. Financial Information - China
9.4. PFIZER CHINA
9.4.1. Background
9.4.2. Business Structure - China
9.4.3. Products/Services - China
9.4.4. Distribution Network - China
9.4.5. Growth strategy - China
9.4.6. Financial Information - China
9.5. SHANGHAI PHARMACEUTICALS HOLDING COMPANY LTD.
9.5.1. Background
9.5.2. Business Structure - China
9.5.3. Products/Services - China
9.5.4. Distribution Network - China
9.5.5. Growth strategy - China
9.5.6. Financial Information - China
9.6. FOSUN PHARMA
9.6.1. Background
9.6.2. Business Structure - China
9.6.3. Products/Services - China
9.6.4. Distribution Network - China
9.6.5. Growth strategy - China
9.6.6. Financial Information - China
